HSPA1A and cancer: Since the groundbreaking discovery by Blachere and colleagues in 1997 of HSP70–peptide complexes inducing antigen-specific CD8+ T-cell responses, HSP70 has emerged as a promising adjuvant in the cancer vaccine therapies [189, 190].